Taken together, these results demonstrate that both atorvastatin and rosuvastatin effectively counteract LPS-induced PAR-2 upregulation, reducing expression at the protein and mRNA levels across distinct colorectal cancer phenotypes. The gene discussed is F2RL1; the disease is colorectal cancer.